OSRH
OSR Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.12
+0.00%Year over year
Reported trailing growth
- Revenue
- +351.8%
- EBITDA
- -74.7%
- EBIT
- —
- EPS
- -16.4%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -13.8%
- EBITDA
- +130.1%
- EPS
- +85.0%
Three-year CAGR
- Revenue
- -17.7%
- EBITDA
- —
- EBIT
- -56.8%
- Net income
- -74.4%
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026